We transitioned our single cell analyses to the 10X Genomics microfluidic partitioning platform to gain higher throughput and deeper sampling of the T cell transcriptomes in tumor, NAT, and PBMC samples than achieved by our targeted scRNAseq platform. Here, BRD2 is linked to neoplasm.